Deutsche Bank’s CAMP4 Therapeutics CAMP Stock Holding History

Deutsche Bank’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,643	Closed	-$18.6K	–	3624
2025 Q1	$18.6K	Buy	+4,643	New	+$22.5K	﹤0.01%	3479

Other funds holding CAMP

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Deutsche Bank's CAMP Position: Q2 2025 in Review

Deutsche Bank sold out of CAMP4 Therapeutics (CAMP) in Q2 2025, closing a stake of 4,643 shares — an estimated $18.6K sold.

Deutsche Bank first reported a position in CAMP in Q1 2025 and held it in 1 quarter. The position peaked at $18.6K in Q1 2025. 29 funds tracked by Wall St. Rank hold CAMP as of Q2 2025.

Deutsche Bank reported no remaining CAMP4 Therapeutics position as of Q2 2025 after selling out during the quarter.
Deutsche Bank sold 4,643 CAMP4 Therapeutics shares in Q2 2025, an estimated $18.6K.
Deutsche Bank first reported a position in CAMP4 Therapeutics in Q1 2025 and held it in 1 quarter.
Deutsche Bank's CAMP4 Therapeutics position peaked at $18.6K in Q1 2025.
29 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.